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The burden of disease in ankylosing
spondylitis (AS) has been hard to grasp
for doctors not directly involved in the
care of these patients. With inflammation
primarily affecting the axial skeleton, the
outward manifestations are limited until
late in the disease, when irreversible
stiffening (ankylosis) and sometimes
deformation progressively limit physical
function and lead to disability. Society
has little patience for patients with AS
where so many people have complaints in
the lower back area, and the insidious
nature of AS allows patients to stay active
participants in society for a very long
time. However, the rapid uptake of
biological agents, the first truly effective
treatment beyond non-steroidal anti-
inflammatory drugs revealed a large
unmet need to alleviate the suffering
caused by pain and stiffness.
The Outcome Measures in
Rheumatology (OMERACT) initiative
started in 1992 with a consensus con-
ference on rheumatoid arthritis (RA) out-
come measures, but very early on
scientists involved in the care of patients
with AS spun off as an independent group
to develop a core set of domains to
measure in AS. This spin off was called
ASAS (Assessment of SpondyloArthritis
international Society), and its results were
first presented at OMERACT 4. Since
then, the group has comprised a tightly
integrated and highly motivated group of
clinical researchers, independently produ-
cing first-class material in the area of
outcome measurement, whilst remaining
closely linked to OMERACT, both
through adoption of OMERACT metho-
dology and by bringing ASAS results to
the OMERACT meetings for endorse-
ment. It is no exaggeration to say that
the development of AS as an indication
for biological treatment was greatly
speeded up by the work of ASAS on
measurement methodology.
Science is never done, so ASAS justifi-
ably went about improving what is
available: in this issue of the Annals
ASAS presents the first step in the
development of a disease activity score
(see page 18).1 Readers probably need no
reminder that the senior author on this
paper, Dr van der Heijde was the first
author on a paper in this journal in 1990
describing the first step in what was to
become the disease activity score (DAS) in
RA2. The construct of disease activity
remains a difficult concept to get a grip on
in RA, and perhaps this is even more so in
AS. Reasons for this include: (a) a lack of
understanding of the pathophysiology of
the disease, forcing us to treat the
phenotype rather than the cause; (b) lack
of measures that comfortably pass the
OMERACT filter of truth, discrimination
and feasibility3; (c) lack of good treatment
options that allow validation of measures.
In the case of AS, despite the availability
of measures and one index (composite of
measures) that had passed the filter (and
allowed the trials of biological agents to
proceed as they did), members of ASAS
felt that there was room for improve-
ment. This led to the initiative to derive a
new index by statistical means, closely
mimicking the development of the DAS.
The article contains a very clear descrip-
tion of the methodology, and is only
briefly summarised here to highlight
important issues. The process started
with a Delphi exercise among experts to
collect all potentially relevant measures,
followed by a meeting to resolve out-
standing problems. This step is highly
important to ensure that no relevant
measures are missed (content validity),
but also to increase the chance of buy-in
to the methodology and adoption of the
final index even if it does not contain a
measure favoured by some experts. It was
decided not to include a measure of
function in the index as a matter of
principle: function can also irreversibly
be affected by damage. In RA, this is one
of the main differences between the DAS
and the WHO/ILAR core set4 5: the exclu-
sion or inclusion of a function measure. In
RA, the Health Assessment Questionnaire
(HAQ) is among the most discriminative
measures for disease activity, despite
some loss of sensitivity in very damaged
patients,6 and I personally think it was a
mistake not to include a measure of
function, at least in the testing phase.
Another problem with the approach
taken, as acknowledged by the authors,
is the lack of patient input in this stage.
Finally, experts suggested also testing
indices not containing acute phase reac-
tants or patient global assessment to
increase feasibility.
The second step was to collect a series
of patients and then to distinguish
between those with high and low disease
activity. In this step lies the eternal
problem of construct validation: it is
inherently circular because one is building
and validating a new (imperfect) measure
by comparing it with another (imperfect)
measure. The authors chose as compar-
ison the decision taken by the treating
doctor whether or not treatment with
tumour necrosis factor (TNF) antagonists
should be started. This approach has high
face validity because presumably such
decisions are primarily taken on the basis
of an implicit assessment of disease
activity. A problem recognised by the
authors was that the decision was theo-
retical: the participating doctors had no
experience with this treatment at the
time the question was asked, and treat-
ment was not really started. This in
contrast with the RA-DAS studies where
data on actual treatment decisions were
used. Notably, ASAS was able to do a
huge survey of 1200 patients through
their network of participating rheumatol-
ogists from many different countries.
The third step was to decrease redun-
dancy of the information in the different
disease activity measures through factor
analysis, followed by discriminant analy-
sis to derive a formula that optimally
distinguishes between the groups (with
high versus low disease activity). This
formula is then back translated to derive a
linear formula with the most important
single measures resulting in the candidate
AS-DAS. A potential weakness of the
approach is that only patients with
complete data can be included, substan-
tially reducing the dataset to about 700
patients. Also, the best formula correctly
classified only 72% of patients as having
either high or low disease activity, a
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modest improvement over the 50/50 a
priori distribution (the equivalent of
tossing a coin).
The final step was to validate the AS-
DAS in a new set of patients, conveni-
ently available in the form of the OASIS
(Outcome in Ankylosing Spondylitis
International Study) cohort. Here, the
authors distinguished two groups of
patients with high and low disease activ-
ity based on the physician global assess-
ment. The result of this impressive
exercise is a set of no less than four
candidate indices ready for further valida-
tion. Topics to be examined include
sensitivity to change, and especially dis-
crimination between a group that changes
little and one that changes a lot (as in the
primary analysis of a placebo-controlled
clinical trial). However, it is highly likely
that any of the four indices will prove
better than any one of the single measures
currently used. This is inherent in the
way the indices have been constructed,
maximising the available information (the
signal) and reducing the random error
associated with measurement (the noise).
In fact, an abstract presented at this year’s
EULAR meeting suggests such an out-
come, with little difference between each
of the four candidate indices applied to
data of the NORDMARD database.7 The
Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI), the venerable
index used to date was beaten, but not
soundly, confirming its high value despite
a much less formal development path.
And all indices correlated well with
patient global assessment (less well with
physician global assessment, surprisingly).
So are all problems of AS disease
activity measurement now settled? Well,
not entirely. Preferably we would like to
end up with only one index. In my view,
the concerns around the inclusion of a
function measure have not been resolved.
And none of the candidates are elegant: all
include the same clunky mix of log or root
transformed factors, and coefficients with
no less than three numerals behind the
decimal. Given that the best discrimina-
tion is only 72%, perhaps other candidates
should be tried that allow a more natural
derivation without calculators or compu-
ters. This has been the lingering problem
with the DAS in its many forms in RA,
and has led to the development of yet
another set of indices by our Austrian
colleagues, the Simplified Disease Activity
Index (SDAI) and the Clinical Disease
Activity Index (CDAI).8 These indices are
simple sums of the component measures
and yet retain much, if not all of the
power of the DAS. Thus, before things are
fixed in stone, the ASAS group should
seriously consider a simpler form of the
index. And ASAS should issue a strong
caveat that much experience in practice is
needed before any index can even be
considered for use to drive decisions in
individual patient care.
But I would not like to end on a
grumpy note. As a member of the
OMERACT Executive I am delighted that
ASAS remains closely linked to
OMERACT. The authors and the ASAS
group are to be congratulated as they go
from strength to strength, building the
methodology that enables the research for
better treatment in AS.
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